UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 135

Sortiert nach

Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment

Biological and Pharmaceutical Bulletin, 2018/04/01, Vol.41(4), pp.592-596

2018

Link zum Volltext

Verfügbarkeit prüfen

Secreted HSP90α-LRP1 Signaling Promotes Tumor Metastasis and Chemoresistance in Pancreatic Cancer

International journal of molecular sciences, 2022-05, Vol.23 (10), p.5532

2022

Link zum Volltext

Verfügbarkeit prüfen

Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents

Molecules (Basel, Switzerland), 2019-06, Vol.24 (11), p.2124

2019

Link zum Volltext

Verfügbarkeit prüfen

The effect of rapid and delayed insemination on reproductive outcome in conventional insemination and intracytoplasmic sperm injection in vitro fertilization cycles

Journal of assisted reproduction and genetics, 2021-10, Vol.38 (10), p.2697-2706

2021

Link zum Volltext

Verfügbarkeit prüfen

Associations between serum total bilirubin, obesity and type 2 diabetes

Diabetology and metabolic syndrome, 2021-12, Vol.13 (1), p.143-143, Article 143

2021

Link zum Volltext

Verfügbarkeit prüfen

Association between intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity and risks of pre-diabetes plus diabetes: an observational study

BMJ open, 2022-02, Vol.12 (2), p.e057820-e057820

2022

Link zum Volltext

Verfügbarkeit prüfen

YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer

Acta pharmaceutica Sinica. B, 2022-06, Vol.12 (6), p.2845-2858

2022

Link zum Volltext

Verfügbarkeit prüfen

A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models

Acta pharmaceutica Sinica. B, 2020-02, Vol.10 (2), p.276-288

2020

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumor Agents via an Immunofluorescence and EdU Labeling Strategy

Frontiers in pharmacology, 2018-07, Vol.9, p.812-812

2018

Link zum Volltext

Verfügbarkeit prüfen

Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]

Acta pharmaceutica Sinica. B, 2023-07, Vol.13 (7), p.3178-3179

2023

Link zum Volltext

Verfügbarkeit prüfen

S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung

Acta pharmaceutica Sinica. B, 2023-03, Vol.13 (3), p.1110-1127

2023

Link zum Volltext

Verfügbarkeit prüfen

Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis

Frontiers in pharmacology, 2019-09, Vol.10, p.1085-1085

2019

Link zum Volltext

Verfügbarkeit prüfen

Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults

BMJ open diabetes research & care, 2021-08, Vol.9 (1), p.e002362

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection

Acta pharmaceutica Sinica. B, 2023-12, Vol.13 (12), p.4945-4962

2023

Link zum Volltext

Verfügbarkeit prüfen

Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs

Nucleic acids research, 2009-12, Vol.37 (22), p.7560

2009

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors

European journal of medicinal chemistry, 2020-02, Vol.188, p.111985, Article 111985

2020

Link zum Volltext

Verfügbarkeit prüfen

Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma

Bioorganic & medicinal chemistry letters, 2022-09, Vol.71, p.128825-128825, Article 128825

2022

Link zum Volltext

Verfügbarkeit prüfen

Previously undescribed tetrahydroanthraquinones from Prismatomeris tetrandra (roxb.) K. Schum with antitumor cell proliferation activities

Phytochemistry (Oxford), 2024-04, Vol.220, p.113995-113995, Article 113995

2024

Link zum Volltext

Verfügbarkeit prüfen

Identification of potential indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors by an FBG-based 3D QSAR pharmacophore model

Journal of molecular graphics & modelling, 2020-09, Vol.99, p.107628-107628, Article 107628

2020

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Biological Evaluation of 4‑Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3‑Kinases and Histone Deacetylases

Journal of medicinal chemistry, 2019-08, Vol.62 (15), p.6992-7014

2019

Link zum Volltext

Verfügbarkeit prüfen

Long non‐coding RNA SNHG6 increases JAK2 expression by targeting the miR‐181 family to promote colorectal cancer cell proliferation

The journal of gene medicine, 2020-12, Vol.22 (12), p.e3262-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Discovery of novel indirubin-3′-monoxime derivatives as potent inhibitors against CDK2 and CDK9

Bioorganic & medicinal chemistry letters, 2015-06, Vol.25 (11), p.2447-2451

2015

Link zum Volltext

Verfügbarkeit prüfen

Novel nitric oxide-releasing derivatives of pyranocarbazole as antitumor agents: Design, synthesis, biological evaluation, and nitric oxide release studies

European journal of medicinal chemistry, 2022-12, Vol.244, p.114832-114832, Article 114832

2022

Link zum Volltext

Verfügbarkeit prüfen

Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer

Cellular and molecular life sciences : CMLS, 2019-09, Vol.76 (17), p.3433-3447

2019

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors

Bioorganic & medicinal chemistry letters, 2020-11, Vol.30 (21), p.127508-127508, Article 127508

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 135

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(128)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment

Secreted HSP90α-LRP1 Signaling Promotes Tumor Metastasis and Chemoresistance in Pancreatic Cancer

Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents

The effect of rapid and delayed insemination on reproductive outcome in conventional insemination and intracytoplasmic sperm injection in vitro fertilization cycles

Associations between serum total bilirubin, obesity and type 2 diabetes

Association between intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity and risks of pre-diabetes plus diabetes: an observational study

YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer

A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models

Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumor Agents via an Immunofluorescence and EdU Labeling Strategy

Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]

S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung

Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis

Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults

Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection

Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs

Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors

Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma

Previously undescribed tetrahydroanthraquinones from Prismatomeris tetrandra (roxb.) K. Schum with antitumor cell proliferation activities

Identification of potential indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors by an FBG-based 3D QSAR pharmacophore model

Design, Synthesis, and Biological Evaluation of 4‑Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3‑Kinases and Histone Deacetylases

Long non‐coding RNA SNHG6 increases JAK2 expression by targeting the miR‐181 family to promote colorectal cancer cell proliferation

Discovery of novel indirubin-3′-monoxime derivatives as potent inhibitors against CDK2 and CDK9

Novel nitric oxide-releasing derivatives of pyranocarbazole as antitumor agents: Design, synthesis, biological evaluation, and nitric oxide release studies

Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer

Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors

Aktive Filter

Suchergebnisse filtern